, Volume 4, Issue 1, pp 145–148 | Cite as


  • Pamela DotyEmail author
  • G. David Rudd
  • Thomas Stoehr
  • Dirk Thomas


Lacosamide is a new chemical entity being investigated as an adjunctive treatment for epilepsy, as well as monotherapy for diabetic neuropathic pain. Lacosamide appears to have a dual mode of action: selective enhancement of sodium channel inactivation and modulation of collapsin response mediator protein-2. Rapidly and completely absorbed after oral administration, lacosamide has an elimination half-life of approximately 13 hours and a low potential for drug interactions. Additionally, lacosamide exhibits linear, dose-proportional pharmacokinetics with low intra- and interpatient variability. Randomized controlled trials of adjunctive lacosamide (200, 400, and 600 mg/day) have demonstrated statistically significant reduction in median seizure frequency compared with placebo. In addition, 50% responder rates for lacosamide (400 and 600 mg/day) were statistically superior to placebo. The most frequently reported adverse events (≥10% of lacosamide-treated patients) included dizziness, headache, and nausea. A double-blind, double-dummy randomized trial of intravenous lacosamide (30- and 60-minute infusion) as replacement for oral lacosamide showed that the safety and tolerability profiles were comparable for intravenous and oral lacosamide. The efficacy and safety results from completed clinical trials, as well as the favorable pharmacokinetic profile, suggest that lacosamide may represent a significant advance in antiepileptic drug therapy.

Key Words

Lacosamide antiepileptic drugs anticonvulsants epilepsy partial-onset seizures 


  1. 1.
    Andurkar SV, Stables JP, Kohn H. The anticonvulsant activities ofN-benzyl 3-methoxypropionamides. Bioorg Med Chem 1999;7: 2381–2389.PubMedCrossRefGoogle Scholar
  2. 2.
    Duncan GE, Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res 2005;67: 81–87.PubMedGoogle Scholar
  3. 3.
    Hovinga CA. SPM-927 (Schwarz Pharma). IDrugs 2003;6: 479–485.PubMedGoogle Scholar
  4. 4.
    Stohr T, Stables JP, Wilcox K, White HS. The pre-clinical profile of the novel anticonvulsant lacosamide. Epilepsia 2005;46(suppl 6): 373. Abstract.Google Scholar
  5. 5.
    LeTiran A, Stables JP, Kohn H. Functionalized amino acid anti-convulsants: synthesis and pharmacological evaluation of conformationally restricted analogues. Bioorg Med Chem 2001;9: 2693–2708.PubMedCrossRefGoogle Scholar
  6. 6.
    Brandt C, Heile A, Potschka H, Stoehr T, Löscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006;47: 1803–1809.PubMedCrossRefGoogle Scholar
  7. 7.
    Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001;43: 11–58.PubMedCrossRefGoogle Scholar
  8. 8.
    Enington AC, Coyne L, Stohr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006;50: 1016–1029.CrossRefGoogle Scholar
  9. 9.
    Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5: 553–564.PubMedCrossRefGoogle Scholar
  10. 10.
    Stoehr T, Lees G, Enington A, et al. Lacosamide has a dual mode of action: selective enhancement of sodium channel slow inactivation and modulation of CRMP-2. Presented at the 9th International Conference on the Mechanisms and Treatment of Neuropathic Pain; November 4, 2005; Bermuda.Google Scholar
  11. 11.
    Czech T, Yang JW, Csaszar E, Kappler J, Baumgartner C, Lubec G. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res 2004;29: 2189–2196.PubMedCrossRefGoogle Scholar
  12. 12.
    Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3β regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 2005;120: 137–149.PubMedCrossRefGoogle Scholar
  13. 13.
    Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Horstmann R. Food does not affect the pharmacokinetics of SPM 927. Epilepsia 2004;45(suppl 7): 307. Abstract.Google Scholar
  14. 14.
    Kropeit D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia 2004;45(suppl 7): 123–124. Abstract.Google Scholar
  15. 15.
    Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002;51: 31–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004;61: 1–48.PubMedCrossRefGoogle Scholar
  17. 17.
    Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia 2002;43(suppl 7): 188. Abstract.Google Scholar
  18. 18.
    Schiltmeyer B, Cawello W, Kropeit D, Hammes W, Horstmann R. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender. Epilepsia 2004;45(suppl 7): 313. Abstract.Google Scholar
  19. 19.
    Kropeit D, Koch B, Schiltmeyer B, Cawello W, Horstmann R, Scharfenecker U. Low drug-interaction potential of lacosamide. J Pain 2005;6(suppl 1): S34. Abstract.Google Scholar
  20. 20.
    Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. SPM 927 does not interact with valproic acid and carbamazepine. Epilepsia 2003;44(suppl 9): 97. Abstract.Google Scholar
  21. 21.
    Kropeit D, Scharfenecker U, Schiltmeyer B, et al. Lacosamide has low potential for drug-drug interaction. Presented at the 59th Annual Meeting of the American Epilepsy Society; December 2, 2005; Washington, DC.Google Scholar
  22. 22.
    Jatuzis D, Biton V, Ben-Menachem E, Abou-Khalil B, Doty P, Rudd GD. Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures. Epilepsia 2005;46(suppl 8): 170. Abstract.Google Scholar
  23. 23.
    Fountain NB, French JA, Privitera MD. Harkoseride: safety and tolerability of a new antiepileptic drug in patients with refractory partial seizures. Epilepsia 2000;41(suppl 7): 169. Abstract.Google Scholar
  24. 24.
    Sachdeo R, Montouris G, Beydoun A, et al. An open-label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures. Neurology 2003;60(suppl 1): A433. Abstract.Google Scholar
  25. 25.
    Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of adjunctive oral lacosamide for the treatment of partial-onset seizures in patients with epilepsy. Neurology 2005;64(suppl 1): A187. Abstract.Google Scholar
  26. 26.
    Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Sullivan T. Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures. Epilepsia 2006;47(suppl 4): 3. Abstract.Google Scholar
  27. 27.
    Biton V, Rosenfeld W, Fountain NB, Vaiciene N, Whitesides J, Sommerville K. Safety, tolerability, and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in subjects with partial seizures. Neurology 2005;64(suppl 1): A119. Abstract.Google Scholar
  28. 28.
    Tatum WO, Galvez R, Benbadis S, Carrazana E. New antiepileptic drugs: into the new millennium. Arch Fam Med 2000;9: 1135–1141.PubMedCrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2007

Authors and Affiliations

  • Pamela Doty
    • 2
    Email author
  • G. David Rudd
    • 2
  • Thomas Stoehr
    • 1
  • Dirk Thomas
    • 1
  1. 1.SCHWARZ PHARMA AGMonheimGermany
  2. 2.SCHWARZ BIOSCIENCES, Inc.Research Triangle Park

Personalised recommendations